盐酸肾上腺素
- 中文名称：
- 盐酸肾上腺素
- 中文别名：
- L(-)-肾上腺素;
(R)-肾上腺素;
肾上腺激素;
L-肾上腺素;
L-肾上腺素盐酸盐单水合物;
副肾碱;
L-3,4-二羟基-alpha-((甲氨基)甲基)苄醇;
(-)-肾上腺素
- 英文名称：
- (R)-adrenaline
- 英文别名：
- (R)-adrenaline;
Adrin;
Epifrin;
L(-)-Epinephrine;
Adrenal;
Adrenan;
L-Epinephrine;
IOP;
Corisol;
Adrine;
L-Adrenaline;
Bosmin;
Exadrin;
Suprel;
(S)-4-(1-hydroxy-2-(methylamino)ethyl)benzene-1,2-diol
- CAS No.：
- 51-43-4
- 分 子 式：
- C9H13NO3
- 分 子 量：
- 183.20400
- 精确分子量：
- 183.09000
- PSA：
- 72.72000
- MDL：
- MFCD00002204
- EINECS：
- 200-098-7
- BRN：
- 2368277
- InChI：
- InChI=1/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/p+1/t9-/m1/s13
- 风险术语：
- 23/24/25-52/53-36/37/38-33
- SDS：
- 查看
盐酸肾上腺素 制备方法及用途
制备方法
-
1.3,4-二羟基-α-甲氨基苯乙酮(即肾上原酮)配制成盐酸盐,在钯类催化下通氢反应。加氢温度为30-35α,压力0.05-0.1MPa,得到的消旋肾上腺素用酒石酸分拆、氢氧化铵中和,得左旋肾上腺素。 2.家畜肾上腺髓质中提取、分离、纯化。 3.人工合成
合成制备方法
1.3,4-二羟基-α-甲氨基苯乙酮（即肾上原酮）配制成盐酸盐，在钯类催化下通氢反应。加氢温度为30-35α，压力0.05-0.1MPa，得到的消旋肾上腺素用酒石酸分拆、氢氧化铵中和，得左旋肾上腺素。
2.家畜肾上腺髓质中提取、分离、纯化。
3.人工合成
用途简介
-
1.非甾体激素类药,也用作止血药安络血的中间体。主要用于过敏性休克、支气管哮喘及心搏骤停的抢救 2.肾上腺素受体激动药。用于解除支气管哮喘、抢救过敏性休克、与局部麻醉药配伍和局部止血、荨麻疹、枯草热、血清反应等过敏性疾病、青光眼等。
用途
1.非甾体激素类药，也用作止血药安络血的中间体。主要用于过敏性休克、支气管哮喘及心搏骤停的抢救
2.肾上腺素受体激动药。用于解除支气管哮喘、抢救过敏性休克、与局部麻醉药配伍和局部止血、荨麻疹、枯草热、血清反应等过敏性疾病、青光眼等。
盐酸肾上腺素 物化性质
- 外观与性状：
- 白色至淡黄色细结晶粉末
- 密度：
- 1.283 g/cm3
- 熔点：
- 208-211ºC
- 沸点：
- 413.1ºC at 760 mmHg
- 闪点：
- 207.9ºC
- 水溶解性：
- <0.01 g/100 mL at 18℃
- 存储条件/存储方法：
- 库房低温,通风,干燥,与食品原料分开存放
- 其它信息：
1. 性状：白色结晶性粉末。
2. 密度（g/mL,25/4℃）： 未确定
3. 相对蒸汽密度（g/mL,空气=1）：未确定
4. 熔点（ºC）：211-212
5. 沸点（ºC,常压）：未确定
6. 沸点（ºC,5.2kPa）：未确定
7. 折射率：未确定
8. 闪点（ºC）：未确定
9. 比旋光度（º，C=2，0.6mol /L盐酸中）：-50～-53.5
10. 自燃点或引燃温度（ºC）：未确定
11. 蒸气压（kPa,25ºC）：未确定
12. 饱和蒸气压（kPa,60ºC）：未确定
13. 燃烧热（KJ/mol）：未确定
14. 临界温度（ºC）：未确定
15. 临界压力（KPa）：未确定
16. 油水（辛醇/水）分配系数的对数值：未确定
17. 爆炸上限（%,V/V）：未确定
18. 爆炸下限（%,V/V）：未确定
19. 溶解性：易溶于矿酸及氢氧化碱溶液，微溶于水，不溶于醇、醚、丙酮、氯仿。无气味，味苦。露置空气及见光色渐深。
盐酸肾上腺素 安全信息
- 包装等级：
- II
- 风险类别：
- 6.1
- 海关代码：
- 2922509090
- 危险类别码：
- R23/24/25;R33;R36/37/38;R52/53
- 安全说明：
- S23-S26-S36/37/39-S45-S61
- RTECS号：
- DO2625000
- 安全标志：
- S45:出现意外或者感到不适，立刻到医生那里寻求帮助（最好带去产品容器标签）。
: - 危险标志：
- T:Toxic
盐酸肾上腺素 毒理性
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- DO2625000
- CHEMICAL NAME :
- Benzyl alcohol, 3,4-dihydroxy-alpha-((methylamino)methyl)-, (-)-
- CAS REGISTRY NUMBER :
- 51-43-4
- LAST UPDATED :
- 199710
- DATA ITEMS CITED :
- 65
- MOLECULAR FORMULA :
- C9-H13-N-O3
- MOLECULAR WEIGHT :
- 183.23
- WISWESSER LINE NOTATION :
- QR BQ DYQ1M1 -L
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 77 mg/kg
- TOXIC EFFECTS :
- Behavioral - hallucinations, distorted perceptions Behavioral - excitement Gastrointestinal - nausea or vomiting
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 43 ug/kg
- TOXIC EFFECTS :
- Cardiac - pulse rate increase, without fall in BP Gastrointestinal - nausea or vomiting Skin and Appendages - sweating
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 7 ug/kg
- TOXIC EFFECTS :
- Brain and Coverings - other degenerative changes Cardiac - other changes
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 8571 ng/kg/80M-I
- TOXIC EFFECTS :
- Cardiac - cardiomyopathy including infarction
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 6 ug/kg
- TOXIC EFFECTS :
- Cardiac - arrhythmias (including changes in conduction)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 285 ug/kg
- TOXIC EFFECTS :
- Cardiac - EKG changes not diagnostic of specified effects Nutritional and Gross Metabolic - other changes
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 3 mg/kg
- TOXIC EFFECTS :
- Vascular - contraction (isolated tissues)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 2 ug/kg
- TOXIC EFFECTS :
- Vascular - regional or general arteriolar constriction
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 16 ug/kg
- TOXIC EFFECTS :
- Behavioral - hallucinations, distorted perceptions Cardiac - change in rate Vascular - BP lowering not characterized in autonomic section
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Multiple routes
- SPECIES OBSERVED :
- Human - infant
- DOSE/DURATION :
- 625 ug/kg/I
- TOXIC EFFECTS :
- Cardiac - pulse rate increase, without fall in BP Lungs, Thorax, or Respiration - cyanosis Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 30 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Administration onto the skin
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 62 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Behavioral - excitement
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 10 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Behavioral - muscle weakness Lungs, Thorax, or Respiration - dyspnea
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 5 mg/kg
- TOXIC EFFECTS :
- Lungs, Thorax, or Respiration - respiratory stimulation
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 150 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intramuscular
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 3500 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 50 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 4 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 1470 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 217 ug/kg
- TOXIC EFFECTS :
- Behavioral - changes in motor activity (specific assay) Cardiac - pulse rate increase, without fall in BP Skin and Appendages - hair
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Unreported
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 10 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Behavioral - excitement Lungs, Thorax, or Respiration - dyspnea
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 5 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 100 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Parenteral
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 5 ug/kg
- TOXIC EFFECTS :
- Cardiac - arrhythmias (including changes in conduction)
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Mammal - cat
- DOSE/DURATION :
- 20 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - cat
- DOSE/DURATION :
- 500 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 30 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 4 mg/kg
- TOXIC EFFECTS :
- Lungs, Thorax, or Respiration - respiratory stimulation
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 50 ug/kg
- TOXIC EFFECTS :
- Lungs, Thorax, or Respiration - respiratory stimulation
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - guinea pig
- DOSE/DURATION :
- 800 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - guinea pig
- DOSE/DURATION :
- 100 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 12 mg/kg/4D-I
- TOXIC EFFECTS :
- Cardiac - changes in heart weight Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 50 ug/kg
- SEX/DURATION :
- male 1 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 6 mg/kg
- SEX/DURATION :
- female 7-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - behavioral
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 1 mg/kg
- SEX/DURATION :
- female 13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 2400 ug/kg
- SEX/DURATION :
- female 1-6 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 10 ug/kg
- SEX/DURATION :
- female 20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 1 mg/kg
- SEX/DURATION :
- female 10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - Central Nervous System
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 5 mg/kg
- SEX/DURATION :
- female 10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 2 mg/kg
- SEX/DURATION :
- female 10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - other effects Nutritional and Gross Metabolic - weight loss or decreased weight gain
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Implant
- DOSE :
- 5760 ug/kg
- SEX/DURATION :
- female 14-21 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - germ cell effects (in offspring)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 16 mg/kg
- SEX/DURATION :
- female 7-10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - other measures of fertility
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 2400 ug/kg
- SEX/DURATION :
- female 6-7 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 5500 ug/kg
- SEX/DURATION :
- female 3 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Fertility - other measures of fertility
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 15 mg/kg
- SEX/DURATION :
- male 15 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - testes, epididymis, sperm duct
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 7500 ug/kg
- SEX/DURATION :
- male 15 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravaginal
- DOSE :
- 90 ug/kg
- SEX/DURATION :
- female 1 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Fertility - other measures of fertility
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 2 mg/kg
- SEX/DURATION :
- female 7-10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - other measures of fertility
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 2 mg/kg
- SEX/DURATION :
- female 7-10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- Cytogenetic analysis
MUTATION DATA
- TYPE OF TEST :
- Mutation in mammalian somatic cells
- TEST SYSTEM :
- Rodent - mouse Lymphocyte
- DOSE/DURATION :
- 100 mg/L
- REFERENCE :
- EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 11,523,1988 *** REVIEWS *** TOXICOLOGY REVIEW CHREAY Chemical Reviews. (American Chemical Soc., Distribution Office Dept. 223, POB 57136, West End Stn., Washington, DC 20037) V.1- 1924- Volume(issue)/page/year: 9,389,1931 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 TOXICOLOGY REVIEW CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year: 2,159,1973 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - A1920 No. of Facilities: 219 (estimated) No. of Industries: 2 No. of Occupations: 7 No. of Employees: 1765 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - A1920 No. of Facilities: 327 (estimated) No. of Industries: 2 No. of Occupations: 10 No. of Employees: 18887 (estimated) No. of Female Employees: 14836 (estimated)
盐酸肾上腺素 MSDS
| Name: | Adrenaline Material Safety Data Sheet |
| Synonym: | Epinephrine; Adrenal; 1-Adrenaline; Adrenaso |
| CAS: | 51-43-4 |
Synonym:Epinephrine; Adrenal; 1-Adrenaline; Adrenaso
Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
| CAS# | Chemical Name | content | EINECS# |
| 51-43-4 | 1,2-benzenediol, 4-[1-hydroxy-2-(methy | 100% | 200-098-7 |
Risk Phrases: 23/24/25 33
Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Toxic by inhalation, in contact with skin and if swallowed. Danger of cumulative effects.Toxic.
Potential Health Effects
Eye:
May cause eye irritation. No information regarding eye irritation and other potential effects was found.
Skin:
May cause skin irritation. No information regarding skin irritation and other potential effects was found.
Ingestion:
Causes gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
May cause respiratory tract irritation. Overexposure may cause dizziness, tremors, restlessness, rapid heart beat, increased blood pressure, hallucinations, acidosis, kidney failure.
Chronic:
Not available.
Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
For small fires, use water spray, dry chemical, carbon dioxide or chemical foam.
Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions.
Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Wash hands before eating. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Do not get on skin or in eyes. Do not ingest or inhale.
Storage:
Keep away from heat and flame. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep containers tightly closed.
Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 51-43-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.
Section 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: white
Odor: odorless
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C9H14ClNO3
Molecular Weight: 219.5559
Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizers.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.
Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 51-43-4: DO2625000 LD50/LC50:
CAS# 51-43-4: Skin, rat: LD50 = 62 mg/kg.
Carcinogenicity:
1,2-benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl] - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.
Section 12 - ECOLOGICAL INFORMATION
Section 13 - DISPOSAL CONSIDERATIONS
Products which are considered hazardous for supply are classified as Special Waste and the disposal of such chemicals is covered by regulations which may vary according to location. Contact a specialist disposal company or the local waste regulator for advice. Empty containers must be decontaminated before returning for recycling.
Section 14 - TRANSPORT INFORMATION
IATA
Shipping Name: ALKALOIDS, SOLID, NOS((-)-Adrenaline)
Hazard Class: 6.1
UN Number: 1544
Packing Group: II
IMO
Shipping Name: ALKALOIDS, SOLID, NOS((-)-Adrenaline)
Hazard Class: 6.1
UN Number: 1544
Packing Group: II
RID/ADR
Shipping Name: ALKALOIDS, SOLID, NOS((-)-Adrenaline)
Hazard Class: 6.1
UN Number: 1544
Packing group: II
USA RQ: CAS# 51-43-4: 1000 lb final RQ; 454 kg final RQ
Section 15 - REGULATORY INFORMATION
European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T
Risk Phrases:
R 23/24/25 Toxic by inhalation, in contact with skin
and if swallowed.
R 33 Danger of cumulative effects.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 51-43-4: 3
Canada
CAS# 51-43-4 is listed on Canada's DSL List.
CAS# 51-43-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 51-43-4 is listed on the TSCA inventory.
SECTION 16 - ADDITIONAL INFORMATION
N/A
盐酸肾上腺素 海关数据
中国海关编码：2922509090
- 概述：
- 2922509090. 其他氨基醇酚、氨基酸酚及其他含氧基氨基化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件：AB. 最惠国关税:6.5%. 普通关税:30.0%
- 申报要素：
- 品名, 成分含量, 用途, 乙醇胺及其盐应报明色度, 乙醇胺及其盐应报明包装
- 监管条件：
- A.入境货物通关单B.出境货物通关单
- 检验检疫：
- R.进口食品卫生监督检验S.出口食品卫生监督检验
- 摘要/Summary：
- 2922509090. other amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%
盐酸肾上腺素 分子结构与计算化学数据
分子结构数据
1、 摩尔折射率：49.33
2、 摩尔体积（cm3/mol）：142.6
3、 等张比容（90.2K）：397.0
4、 表面张力（dyne/cm）：59.9
5、 极化率（10-24cm3）：19.55
计算化学数据
1.疏水参数计算参考值（XlogP）:无
2.氢键供体数量:4
3.氢键受体数量:4
4.可旋转化学键数量:3
5.互变异构体数量:10
6.拓扑分子极性表面积72.7
7.重原子数量:13
8.表面电荷:0
9.复杂度:154
10.同位素原子数量:0
11.确定原子立构中心数量:1
12.不确定原子立构中心数量:0
13.确定化学键立构中心数量:0
14.不确定化学键立构中心数量:0
15.共价键单元数量:1
